P/B
—
Alvotech
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
$1.6B
Market Cap • 10/23/2026
2018
(8 years)
Founded
2022
(4 years ago)
IPO
NASDAQ
Listing Exchange
Iceland
Country
Valuation
P/S
3,3
P/EBITDA
18,4
P/OCF
—
P/FCF
—
P/E
—
BVPS
—
EPS
—
Market Cap
Market Cap
1,6B
EV
2,9B
EV/Revenue
6
EV/EBITDA
33,1
EV/EBIT
61,9
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-10,1%
Total Yield
-10,1%
Payout
0%
Retained Earnings
-2,5B
Profitability
Gross Margin
60,4%
EBITDA Margin
18,1%
EBIT Margin
9,7%
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
28%
Capex/Revenue
12,7%
Capex/D&A
151,7%
Capex/OCF
-31,5%
SBC/OCF
—
% PPE
32,5%
% Goodwill
0,8%
ROE
98,5%
ROIC
4,3%
Growth
CAGR Revenue 5Y
53,2%
CAGR Net Income 5Y
-12,1%
CAGR OCF 5Y
13%
Leverage
N.D./EBITDA
14,7
Debt/Equity
0%
Current Ratio
1,6
Quick Ratio
0,6
Interest Coverage
29,9%
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!